Exendin-4 differentially modulates essential functions of human dermal fibroblasts under normoglycemic and

M Wolak1, J Drobnik2, E Bojanowska3

  • 1Department of Behavioral Pathophysiology, Medical University of Lodz, Lodz, Poland.

Insights

Exendin-4, a GLP-1 analog, shows improved wound healing benefits in normal glucose conditions. High glucose levels attenuate its positive effects on fibroblast functions and extracellular matrix production.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Dermatology

Background:

  • Exendin-4, a glucagon-like peptide-1 analog, is being investigated for wound healing, particularly in diabetic conditions.
  • The impact of exendin-4 on dermal fibroblast production of extracellular matrix (ECM) and regulatory compounds remains largely unknown.

Purpose of the Study:

  • To investigate the effects of exendin-4 on human skin fibroblast functions critical for wound healing.
  • To compare exendin-4's efficacy under normoglycemic and hyperglycemic conditions.

Main Methods:

  • Human skin fibroblasts were cultured in normal (5.6 mmol/l) or high (25 mmol/l) glucose media.
  • Cells were treated with varying concentrations of exendin-4 (0-100 nmol/l).
  • Fibroblast proliferation (BrdU assay), metabolic activity (MTT assay), MMP-9, TIMP-1, FGF-1, LDH leakage, and GAG content were measured.

Main Results:

  • Exendin-4 enhanced proliferation and metabolic activity in normoglycemic conditions but not in hyperglycemia.
  • Exendin-4 reduced MMP-9 secretion and increased TIMP-1 and GAG content under both glucose conditions.
  • Exendin-4's effects on FGF-1 and LDH leakage varied between normoglycemic and hyperglycemic environments, with generally reduced benefits in high glucose.

Conclusions:

  • Exendin-4's impact on fibroblast ECM production and regulatory proteins is glucose-dependent.
  • The beneficial effects of exendin-4 on fibroblast function, crucial for wound healing, are more pronounced under normoglycemic conditions.
  • Hyperglycemia significantly attenuates the positive therapeutic effects of exendin-4 on dermal fibroblasts.

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
4.7K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
469
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.5K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
375